Cancer treatment company BioOra secures $4m funding to scale up
The raise comes ahead of a much larger one next year once first results are through from its second patient trial.
BioOra says automation has enabled it to lower the cost of manufacturing.
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Pioneering cancer treatment company BioOra has closed a $4 million pre-Series A funding round that will help scale up its team and manufacturing.
BioOra is the only licensed manufacturer in New Zealand of chimeric antigen receptor (Car-T) cell therapeutics, which has effectively treated certain
Want to read more? It's easy.
Choose your subscription
Already have an account? Login
Smartphone Only Subscription
NZ$29.95 / monthly
Monthly Premium Online Subscription
NZ$49.95 / monthly
Smartphone Only Annual Subscription
NZ$299.00 / yearly
Yearly Premium Online Subscription
NZ$499.00 / yearly
Premium Group Membership 10 Users
NZ$385+GST / monthly
$38.5 per user - Pay by monthly
credit card debit
Premium Group Membership 20 Users
NZ$660+GST / monthly
$33 per user - Pay by monthly
credit card debit
Premium Group Membership 50 Users
NZ$1375+GST / monthly
$27.5 per user - Pay by monthly
credit card debit
Premium Group Membership 100 Users
NZ$2100+GST / monthly
$21 per user - Pay by monthly
credit card debit
Yearly Premium Online Subscription + NBR Marketplace
NZ$999.00 / yearly
Individual
Group membership
NBR Marketplace
Student
Exclusive FREE offer for uni students studying at a New Zealand university (valued at $499).
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
